title: Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
abstract: BACKGROUND
  Previous studies have shown effectiveness of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. This double-blind study compared efficacy of l Hz rTMS over the right prefrontal dorsolateral cortex with venlafaxine ER in the treatment of resistant depression.
  
  
  METHODS
  A total of 60 inpatients with depressive disorder (DSM-IV criteria), who previously did not respond to at least one antidepressant treatment, were randomly assigned to 1 Hz rTMS with placebo and venlafaxine ER with sham rTMS for 4 weeks. The primary outcome measure was score change in the Montgomery-Asberg Depression Rating Scale (MADRS). We also used Clinical Global Impression (CGI) and Beck Depressive. Inventory-Short Form (BDI-SF). The response was defined as a >or=50% reduction of MADRS score.
  
  
  RESULTS
  There were no significant differences between treatment groups in MADRS (p=0.38), BDI-SF (p=0.56) and CGI (p=0.17) scores from baseline to endpoint. Response rates for rTMS (33%) and venlafaxine (39%) as well as remission (MADRS score<or=10 points) rates (19% vs. 23%) and drop-out rate did not differ between treatment groups. There were significant reductions of MADRS, CGI and BDI-SF scores in both groups.
  
  
  CONCLUSIONS
  Small sample size. No placebo arm was included for ethical reasons, because both treatments have previously been reported to be more effective than placebo. Relatively short duration of antidepressant treatment.
  
  
  CONCLUSIONS
  The findings of this study suggest that, at least in the acute treatment, the right sided rTMS produces clinically relevant reduction of depressive symptomatology in patients with resistant depression comparable to venlafaxine ER. Larger sample sizes are required to confirm these results.
authors.affiliation: Prague Psychiatric Centre, Ustavni 91, Prague 8 - Bohnice, 181 03, Czech Republic.
authors.forename: Martin
authors.initials: M
authors.lastname: Bares
authors.forename: Miloslav
authors.initials: M
authors.lastname: Kopecek
authors.forename: Tomas
authors.initials: T
authors.lastname: Novak
authors.forename: Pavla
authors.initials: P
authors.lastname: Stopkova
authors.forename: Peter
authors.initials: P
authors.lastname: Sos
authors.forename: Jiri
authors.initials: J
authors.lastname: Kozeny
authors.forename: Martin
authors.initials: M
authors.lastname: Brunovsky
authors.forename: Cyril
authors.initials: C
authors.lastname: Höschl
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010552:Personality Assessment / Q000706:statistics & numerical data; D017397:Prefrontal Cortex / Q000187:drug effects / Q000503:physiopathology; D011594:Psychometrics; D050781:Transcranial Magnetic Stimulation / Q000379:methods*; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride